24S-hydroxycholesterol in plasma: A marker of cholesterol turnover in neurodegenerative diseases

Biochimie

Volumn 95, Issue 3, 2013, Pages 595-612

  Leoni, Valerio ^a   Caccia, Claudio ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Biomarker; Dementia; LXR; Mass spectrometry; Oxysterols

Indexed keywords

24 HYDROXYCHOLESTEROL; 26 HYDROXYCHOLESTEROL; AMYLOID PRECURSOR PROTEIN; CHOLESTEROL; CHOLESTEROL DERIVATIVE; FLUCONAZOLE; LIPOPROTEIN; OXYSTEROL; PRAVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; VORICONAZOLE;

ALZHEIMER DISEASE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN; BRAIN ATROPHY; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DEGENERATIVE DISEASE; HEREDITY; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; MULTIPLE SCLEROSIS; NERVE CELL; NONHUMAN; NUTRITION; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; BRAIN; HUMANS; HYDROXYCHOLESTEROLS; NEURODEGENERATIVE DISEASES;

EID: 84874107996     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2012.09.025     Document Type: Review

References (183)

1. V.W. Rodwell, J.J. Nordstrom, and J.J. Mitschelen Regulation of HMG-CoA reductase Adv. Lipid Res. 14 1976 1 74
2. H.J. Kempen, J.F. Glatz, J.A. Gevers Leuven, H.A. van der Voort, and M.B. Katan Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans J. Lipid Res. 29 1988 1149 1155
3. K. Bloch, R.B. Clayton, and P.B. Schneider Synthesis of lanosterol in vivo J. Biol. Chem. 224 1957 175 183
4. N.R. Matthan, M. Raeini-Sarjaz, A.H. Lichtenstein, L.M. Ausman, and P.J. Jones Deuterium uptake and plasma cholesterol precursor levels correspond as methods for measurement of endogenous cholesterol synthesis in hypercholesterolemic women Lipids 35 2000 1037 1044
5. D.W. Russell The enzymes, regulation, and genetics of bile acid synthesis Annu. Rev. Biochem. 72 2003 137 174
6. W.C. Duane, and N.B. Javitt 27-Hydroxycholesterol: production rates in normal human subjects J. Lipid Res. 40 1999 1194 1199
7. A.J. Brown, and W. Jessup Oxysterols, sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis Mol. Aspects Med. 30 2009 111 122
8. T.A. Miettinen, R.S. Tilvis, and Y.A. Kesäniemi Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population Am. J. Epidemiol. 131 1990 20 31
9. J.M. Dietschy, and S.D. Turley Thematic review series, brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal J. Lipid Res. 45 2004 1375 1397
10. F.R. Maxfield, and I. Tabas Role of cholesterol and lipid organization in disease Nature 438 2005 612 621
11. J.A. Allen, R.A. Halverson-Tamboli, and M.M. Rasenick Lipid raft microdomains and neurotransmitter signalling Nat. Rev. Neurosci. 8 2007 128 140
12. A.R. Koudinov, and N.V. Koudinova Essential role for cholesterol in synaptic plasticity and neuronal degeneration FASEB J. 15 2001 1858 1860
13. F.W. Pfrieger Cholesterol homeostasis and function in neurons of the central nervous system Cell. Mol. Life Sci. 60 2003 1158 1171
14. F.W. Pfrieger Outsourcing in the brain, do neurons depend on cholesterol delivery by astrocytes? Bioessays 25 2003 72 78
15. F.W. Pfrieger, and N. Ungerer Cholesterol metabolism in neurons and astrocytes Prog. Lipid Res. 50 2011 357 371
16. G.J. Snipe, and U. Suter Cholesterol and myelin R. Bitmaan, Subcellular Biochemistry Cholesterol: Its Function and Metabolism in Biology and Medicine, New York 1997 173 204
17. I. Björkhem, and S. Meaney Brain cholesterol: long secret life behind a barrier Arterioscler. Thromb. Vasc. Biol. 24 2004 806 815
18. A. Wechsler, A. Brafman, M. Shafir, M. Heverin, H. Gottlieb, G. Damari, S. Gozlan-Kelner, I. Spivak, O. Moshkin, E. Fridman, Y. Becker, R. Skaliter, P. Einat, A. Faerman, I. Björkhem, and E. Feinstein Generation of viable cholesterol-free mice Science 302 2003 2087
19. G. Saher, S. Quintes, W. Mobius, M.C. Wehr, E.M. Kramer-Albers, B. Brugger, and K.A. Nave Cholesterol regulates the endoplasmic reticulum exit of the major membrane protein P0 required for peripheral myelin compaction J. Neurosci. 29 2009 6094 6104
20. W. Baron, and D. Hoekstra On the biogenesis of myelin membranes: sorting, trafficking and cell polarity FEBS Lett. 584 2010 1760 1770
21. G. Saher, B. Brügger, C. Lappe-Siefke, W. Möbius, R. Tozawa, M.C. Wehr, F. Wieland, S. Ishibashi, and K.A. Nave High cholesterol level is essential for myelin membrane growth Nat. Neurosci. 8 2005 468 475
22. R.E. Pitas, J.K. Boyles, S.H. Lee, D. Foss, and R.W. Mahley Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins Biochim. Biophys. Acta 917 1987 148 161
23. G. Bu Apolipoprotein E and its receptors in Alzheimer's disease, pathways, pathogenesis and therapy Nat. Rev. Neurosci. 10 2009 333 344
24. E. Posse de Chaves, and V. Narayanaswami Apolipoprotein E and cholesterol in aging and disease in the brain Future Lipidol. 3 2008 505 530
25. I. Björkhem, V. Leoni, and S. Meaney Genetic connections between neurological disorders and cholesterol metabolism J. Lipid Res. 51 2010 2489 2503
26. D. Lütjohann, O. Breuer, G. Ahlborg, I. Nennesmo, Å. Siden, U. Diczfalusy, and I. Björkhem Cholesterol homeostasis in human brain, evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation Proc. Natl. Acad. Sci. U.S.A. 93 1996 9799 9804
27. C. Xie, E.G. Lund, S.D. Turley, D.W. Russell, and J.M. Dietschy Quantification of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration J. Lipid Res. 44 2003 1780 1789
28. E.G. Lund, J.M. Guileyardo, and D.W. Russell cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain Proc. Natl. Acad. Sci. U.S.A. 6 1999 7238 7243
29. D.M. Ramirez, S. Andersson, and D.W. Russell Neuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brain J. Comp. Neurol. 507 2008 1676 1693
30. I. Björkhem Crossing the barrier, oxysterols as cholesterol transporters and metabolic modulators in the brain J. Intern. Med. 260 2006 493 508
31. Y. Ohyama, S. Meaney, M. Heverin, L. Ekström, A. Brafman, M. Shafir, U. Andersson, M. Olin, G. Eggertsen, U. Diczfalusy, E. Feinstein, and I. Björkhem Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes J. Biol. Chem. 281 2006 3810 3820
32. N. Bogdanovic, L. Bretillon, E.G. Lund, U. Diczfalusy, L. Lannfelt, B. Winblad, D.W. Russell, and I. Björkhem On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells Neurosci. Lett. 314 2001 45 48
33. J. Brown III, C. Theisler, S. Silberman, D. Magnuson, N. Gottardi-Littell, J.M. Lee, D. Yager, J. Crowley, K. Sambamurti, M.M. Rahman, A.B. Reiss, C.B. Eckman, and B. Wolozin Differential expression of cholesterol hydroxylases in Alzheimer's disease J. Biol. Chem. 279 2004 34674 34681
34. X. He, A.M. Jenner, W.Y. Ong, A.A. Farooqui, and S.C. Patel Lovastatin modulates increased cholesterol and oxysterol levels and has a neuroprotective effect on rat hippocampal neurons after kainate injury J. Neuropathol. Exp. Neurol. 65 2006 652 663
35. C.E. Teunissen, S. Floris, M. Sonke, C.D. Dijkstra, H.E. De Vries, and D. Lütjohann 24S-hydroxycholesterol in relation to disease manifestations of acute experimental autoimmune encephalomyelitis J. Neurosci. Res. 85 2007 1499 1505
36. C.M. Cartagena, F. Ahmed, M.P. Burns, A. Pajoohesh-Ganji, D.T. Pak, A.I. Faden, and G.W. Rebeck Cortical injury increases cholesterol 24S hydroxylase (Cyp46) levels in the rat brain J. Neurotrauma 25 2008 1087 1098
37. K. Smiljanic, I. Lavrnja, A. Mladenovic Djordjevic, S. Ruzdijic, M. Stojiljkovic, S. Pekovic, and S. Kanazir Brain injury induces cholesterol 24-hydroxylase (Cyp46) expression in glial cells in a time-dependent manner Histochem. Cell. Biol. 134 2010 159 169
38. T.J. Kotti, D.M. Ramirez, B.E. Pfeiffer, K.M. Huber, and D.W. Russell Brain cholesterol turnover required for geranylgeraniol production and learning in mice Proc. Natl. Acad. Sci. U.S.A. 103 2006 3869 3874
39. D.W. Russell, R.W. Halford, D.M. Ramirez, R. Shah, and T. Kotti Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain Annu. Rev. Biochem. 78 2009 1017 1040
40. M. Shafaati, M. Olin, A. Båvner, H. Pettersson, B. Rozell, S. Meaney, P. Parini, and I. Björkhem Enhanced production of 24S-hydroxycholesterol is not sufficient to drive liver X receptor target genes in vivo J. Intern. Med. 270 2011 377 387
41. K.M. Thelen, K.M. Rentsch, U. Gutteck, M. Heverin, M. Olin, U. Andersson, A. von Eckardstein, I. Björkhem, and D. Lütjohann Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin J. Pharmacol. Exp. Ther. 316 2006 1146 1152
42. H. Sanati, P. Belanger, R. Fratti, and M. Ghannoum A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei Antimicrob. Agents Chemother. 41 1997 2492 2496
43. M. Shafaati, N. Mast, O. Beck, R. Nayef, G.Y. Heo, L. Björkhem-Bergman, D. Lütjohann, I. Björkhem, and I.A. Pikuleva The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase in vitro and in vivo J. Lipid Res. 51 2010 318 323
44. E.Y. Bryleva, M.A. Rogers, C.C. Chang, F. Buen, B.T. Harris, E. Rousselet, N.G. Seidah, S. Oddo, F.M. LaFerla, T.A. Spencer, W.F. Hickey, and T.Y. Chang ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD Proc. Natl. Acad. Sci. U.S.A. 107 2010 3081 3086
45. J.F. Oram, and J.W. Heinecke ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease Physiol. Rev. 85 2005 1343 1372
46. A. Brooks-Wilson, M. Marcil, S.M. Clee, L.H. Zhang, K. Roomp, M. van Dam, L. Yu, C. Brewer, J.A. Collins, H.O. Molhuizen, O. Loubser, B.F. Ouelette, K. Fichter, K.J. Ashbourne-Excoffon, C.W. Sensen, S. Scherer, S. Mott, M. Denis, D. Martindale, J. Frohlich, K. Morgan, B. Koop, S. Pimstone, J.J. Kastelein, J. Genest Jr., and M.R. Hayden Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency Nat. Genet. 22 1999 336 345
47. V. Hirsch-Reinshagen, S. Zhou, B.L. Burgess, L. Bernier, S.A. McIsaac, J.Y. Chan, G.H. Tansley, J.S. Cohn, M.R. Hayden, and C.L. Wellington Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain J. Biol. Chem. 279 2004 41197 41207
48. S.E. Wahrle, H. Jiang, M. Parsadanian, J. Legleiter, X. Han, J.D. Fryer, T. Kowalewski, and D.M. Holtzman ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE J. Biol. Chem. 279 2004 40987 40993
49. J.M. Karasinska, F. Rinninger, D. Lütjohann, P. Ruddle, S. Franciosi, J.K. Kruit, R.R. Singaraja, V. Hirsch-Reinshagen, J. Fan, L.R. Brunham, N. Bissada, R. Ramakrishnan, C.L. Wellington, J.S. Parks, and M.R. Hayden Specific, loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function J. Neurosci. 29 2009 3579 3589
50. O. Levi, D. Lutjohann, A. Devir, K. von Bergman, T. Hartmann, and D.M. Michaelson Regulation of hippocampal cholesterol metabolism by ApoE and environmental stimulation J. Neurochem. 95 2005 987 997
51. P.J. Jansen, D. Lütjohann, K.M. Thelen, K. von Bergmann, F. van Leuven, F.C. Ramaekers, and M. Monique Absence of ApoE upregulates murine brain ApoD and ABCA1 levels, but does not affect brain sterol levels, while human ApoE3 and human ApoE4 upregulate brain cholesterol precursor levels J. Alzheimers Dis. 18 2009 319 329
52. P.T. Tarr, and P.A. Edwards ABCG1 and ABCG4 are coexpressed in neurons and astrocytes of the CNS and regulate cholesterol homeostasis through SREBP-2 J. Lipid Res. 49 2008 169 182
53. N. Wang, L. Yvan-Charvet, D. Lütjohann, M. Mulder, T. Vanmierlo, T.W. Kim, and A.R. Tall ATP-binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain FASEB J. 22 2008 1073 1082
54. B. Karten, R.B. Campenot, D.E. Vance, and J.E. Vance Expression of ABCG1, but not ABCA1, correlates with cholesterol release by cerebellar astroglia J. Biol. Chem. 281 2006 4049 4057
55. B.L. Burgess, P.F. Parkinson, M.M. Racke, V. Hirsch-Reinshagen, J. Fan, C. Wong, S. Stukas, L. Theroux, J.Y. Chan, J. Donkin, A. Wilkinson, D. Balik, B. Christie, J. Poirier, D. Lütjohann, R.B. Demattos, and C.L. Wellington ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo J. Lipid Res. 49 2008 1254 1267
56. T. Vanmierlo, K. Rutten, L.C. van Vark-van der Zee, S. Friedrichs, V.W. Bloks, A. Blokland, F.C. Ramaekers, E. Sijbrands, H. Steinbusch, J. Prickaerts, F. Kuipers, D. Lütjohann, and M. Mulder Cerebral accumulation of dietary derivable plant sterols does not interfere with memory and anxiety related behavior in Abcg5-/- mice Plant Foods Hum. Nutr. 66 2011 149 156
57. K. Abildayeva, P.J. Jansen, V. Hirsch-Reinshagen, V.W. Bloks, A.H. Bakker, J. Ramaekers, F.C. de Vente, A.K. Groen, C.L. Wellington, F. Kuipers, and M. Mulder 24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux J. Biol. Chem. 281 2006 12799 12808
58. J.D. Horton, J.L. Goldstein, and M.S. Brown SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver J. Clin. Invest. 109 2002 1125 1131
59. C.M. Cartagena, M.P. Burns, and G.W. Rebeck 24S-hydroxycholesterol effects on lipid metabolism genes are modeled in traumatic brain injury Brain Res. 1319 2010 1 12
60. Y. Wang, S. Muneton, J. Sjövall, J.N. Jovanovic, and W.J. Griffiths The effect of 24S-hydroxycholesterol on cholesterol homeostasis in neurons: quantitative changes to the cortical neuron proteome J. Proteome Res. 7 2008 1606 1614
61. D.S. Howland, S.P. Trusko, M.J. Savage, A.G. Reaume, D.M. Lang, J.D. Hirsch, N. Maeda, R. Siman, B.D. Greenberg, R.W. Scott, and D.G. Flood Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol J. Biol. Chem. 273 1998 16576 16582
62. Y. Liu, D.A. Peterson, and D. Schubert Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis Proc. Natl. Acad. Sci. U.S.A. 95 1998 13266 13271
63. A.M. Nicholson, and A. Ferreira Increased membrane cholesterol might render ature hippocampal neurons more susceptible to B-amyloid-induced calpain activation and tau toxicity J. Neurosci. 29 2009 4640 4651
64. W.J. Strittmatter, A.M. Saunders, M. Goedert, K.H. Weisgraber, L.M. Dong, R. Jakes, D.Y. Huang, M. Pericak-Vance, D. Schmechel, and A.D. Roses Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease Proc. Natl. Acad. Sci. U.S.A. 91 1994 11183 11186
65. W.S. Kim, A.S. Rahmanto, A. Kamili, K.A. Rye, G.J. Guillemin, I.C. Gelissen, W. Jessup, A.F. Hill, and B. Garner Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation J. Biol. Chem. 282 2007 2851 2861
66. J.R. Prasanthi, A. Huls, S. Thomasson, A. Thompson, E. Schommer, and O. Ghribi Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells Mol. Neurodegener. 4 2009
67. M. Heverin, N. Bogdanovic, D. Lütjohann, T. Bayer, I. Pikuleva, L. Bretillon, U. Diczfalusy, B. Winblad, and I. Björkhem Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease J. Lipid Res. 45 2004 186 193
68. D. Famer, S. Meaney, M. Mousavi, I. Björkhem, and M. Crisby Regulation of á-and â-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the á-secretase pathway Biochem. Biophys. Res. Commun. 359 2007 46 50
69. I. Björkhem, M. Heverin, V. Leoni, and S. Meaney Oxysterols and Alzheimer's disease Acta Neurol. Scand. Suppl. 185 2006 43 49
70. I. Björkhem, A. Cedazo-Minguez, V. Leoni, and S. Meaney Oxysterols and neurodegenerative diseases Mol. Aspects Med. 30 2009 171 179
71. A.J. Beel, C.K. Mobley, H.J. Kim, F. Tian, A. Hadziselimovic, B. Jap, J.H. Prestegard, and C.R. Sanders Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor? Biochemistry 47 2008 9428 9446
72. R.M. Epand Proteins and cholesterol-rich domains Biochim. Biophys. Acta 1778 2008 1576 1582
73. V. Leoni, A. Solomon, and M. Kivipelto Links between ApoE, brain cholesterol metabolism, tau and amyloid beta-peptide in patients with cognitive impairment Biochem. Soc. Trans. 38 2010 1021 1025
74. E. Hudry, D. Van Dam, W. Kulik, P.P. De Deyn, F.S. Stet, O. Ahouansou, A. Benraiss, A. Delacourte, P. Bougnères, P. Aubourg, and N. Cartier Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease Mol. Ther. 18 2010 44 53
75. R.W. Halford, and D.W. Russell Reduction of cholesterol synthesis in the mouse brain does not affect amyloid formation in Alzheimer's disease, but does extend lifespan Proc. Natl. Acad. Sci. U.S.A. 106 2009 3502 3506
76. H. Kölsch, D. Lütjohann, A. Tulke, I. Björkhem, and M.L. Rao The neurotoxic effect of 24-hydroxycholesterol on SH-SY5Y human neuroblastoma cells Brain Res. 818 1999 171 175
77. K. Yamanaka, Y. Saito, T. Yamamori, Y. Urano, and N. Noguchi 24(S)-hydroxycholesterol induces neuronal cell death through necroptosis, a form of programmed necrosis J. Biol. Chem. 286 2011 24666 24673
78. P. Gamba, G. Leonarduzzi, E. Tamagno, M. Guglielmotto, G. Testa, B. Sottero, S. Gargiulo, F. Biasi, A. Mauro, J. Viña, and G. Poli Interaction between 24-hydroxycholesterol, oxidative stress, and amyloid-â in amplifying neuronal damage in Alzheimer's disease: three partners in crime Aging Cell. 10 2011 403 417
79. I. Björkhem, D. Lütjohann, U. Diczfalusy, L. Ståhle, G. Ahlborg, and J. Wahren Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation J. Lipid Res. 39 1998 1594 1600
80. L. Bretillon, D. Lütjohann, L. Ståhle, T. Widhe, L. Bindl, G. Eggersten, U. Diczfalusy, and I. Bjorkhem Plasma levels of 24S- hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface J. Lipid Res. 41 2000 840 845
81. G.L. Vega, M.F. Weiner, A.M. Lipton, K. Von Bergmann, D. Lütjohann, C. Moore, and D. Svetlik Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease Arch. Neurol. 60 2003 510 515
82. L. Bretillon, Å. Siden, L.O. Wahlund, D. Lütjohann, L. Minthon, M. Crisby, J. Hillert, G.C. Groth, U. Diczfalusy, and I. Björkhem Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases Neurosci. Lett. 293 2000 87 90
83. V. Leoni, C. Mariotti, S.J. Tabrizi, M. Valenza, E.J. Wild, S.M. Henley, N.Z. Hobbs, M.L. Mandelli, M. Grisoli, I. Björkhem, E. Cattaneo, and S. Di Donato Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease Brain 131 2008 2851 2859
84. V. Leoni, C. Mariotti, L. Nanetti, E. Salvatore, F. Squitieri, A.R. Bentivoglio, M. Bandettini Del Poggio, S. Piacentini, D. Monza, M. Valenza, E. Cattaneo, and S. Di Donato Whole body cholesterol metabolism is impaired in Huntington's disease Neurosci. Lett. 494 2011 245 249
85. V. Leoni, T. Masterman, U. Diczfalusy, G. De Luca, J. Hillert, and I. Björkhem Changes in human plasma levels of 24S-hydroxycholesterol during progression of multiple sclerosis Neurosci. Lett. 331 2002 163 166
86. A. Solomon, V. Leoni, M. Kivipelto, A. Besga, A.R. Oksengård, P. Julin, L. Svensson, L.O. Wahlund, N. Andreasen, B. Winblad, H. Soininen, and I. Björkhem Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease Neurosci. Lett. 462 2009 89 93
87. T.N. van den Kommer, M.G. Dik, H.C. Comijs, K. Fassbender, D. Lütjohann, and C. Jonker Total cholesterol and oxysterols: early markers for cognitive decline in elderly? Neurobiol. Aging 30 2009 534 545
88. I. Burkard, A. von Eckardstein, A. Waeber, P. Vollenweider, and K.M. Rentsch Lipoprotein distribution and biological variation of 24S- and 27-hydroxycholesterol in healthy volunteers Atherosclerosis 194 2007 71 78
89. A. Babiker, and U. Diczfalusy Transport of side-chain oxidized oxysterols in the human circulation Biochim. Biophys. Acta 1392 1998 333 339
90. L.J. Meng, W.J. Griffiths, H. Nazer, Y. Yang, and J. Sjövall High levels of (24S)-24-hydroxycholesterol 3-sulfate, 24-glucuronide in the serum and urine o children with severe cholestatic liver disease J. Lipid Res. 38 1997 926 934
91. G. Lupattelli, S. De Vuono, and E. Mandarino Patterns of cholesterol metabolism: pathophysiological and therapeutic implications for dyslipidemias and the metabolic syndrome Nutr. Metab. Cardiovasc. Dis. 21 2011 620 627
92. R.C. Seet, C.Y. Lee, W.M. Loke, S.H. Huang, H. Huang, W.F. Looi, E.S. Chew, A.M. Quek, E.C. Lim, and B. Halliwell Biomarkers of oxidative damage in cigarette smokers: which biomarkers might reflect acute versus chronic oxidative stress? Free Radic. Biol. Med. 50 2011 1787 1793
93. A. Serrano-Pozo, G.L. Vega, D. Lütjohann, J.J. Locascio, M.K. Tennis, A. Deng, A. Atri, B.T. Hyman, M.C. Irizarry, and J.H. Growdon Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers Alzheimer Dis. Assoc. Disord. 24 2010 220 226
94. S. Locatelli, D. Lütjohann, H.H. Schmidt, C. Otto, U. Beisiegel, and K. von Bergmann Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain Arch. Neurol. 59 2002 213 216
95. T.E. Vogelvang, V. Mijatovic, M.J. van der Mooren, U. Pinsdorf, K. von Bergmann, J.C. Netelenbos, and D. Lütjohann Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women Maturitas 50 2005 312 320
96. S. Sauder, H. Kölsch, D. Lütjohann, A. Schulz, K. von Bergmann, W. Maier, and R. Heun Influence of peroxisome proliferator-activated receptor gamma gene polymorphism on 24S-hydroxycholesterol levels in Alzheimer's patients J. Neural Transm. 112 2005 1381 1389
97. A. Papassotiropoulos, D. Lütjohann, M. Bagli, S. Locatelli, F. Jessen, M.L. Rao, W. Maier, I. Björkhem, K. von Bergmann, and R. Heun Plasma 24S-hydroxycholesterol, a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease Neuroreport 11 2000 1959 1962
98. H. Kölsch, R. Heun, A. Kerksiek, K.V. Bergmann, W. Maier, and W. Lutjohann Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients Neurosci. Lett. 368 2004 303 308
99. J. Koschack, D. Lütjohann, C. Schmidt-Samoa, and E. Irle Serum 24S-hydroxycholesterol and hippocampal size in middle-aged normal individuals Neurobiol. Aging 30 2009 898 902
100. C.E. Teunissen, C.D. Dijkstra, C.H. Polman, E.L. Hoogervorst, K. von Bergmann, and D. Lütjohann Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients Neurosci. Lett. 347 2003 159 162
101. V. Danylaité Karrenbauer, V. Leoni, E.T. Lim, G. Giovannoni, G.T. Ingle, J. Sastre-Garriga, A.J. Thompson, W. Rashid, G. Davies, J. Hillert, D.H. Miller, I. Björkhem, and T. Masterman Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis Clin. Neurol. Neurosurg. 108 2006 456 460
102. V. Leoni, L. Strittmatter, G. Zorzi, F. Zibordi, S. Dusi, B. Garavaglia, P. Venco, C. Caccia, A.L. Souza, A. Deik, C.B. Clish, M. Rimoldi, E. Ciusani, E. Bertini, N. Nardocci, V.K. Mootha, and V. Tiranti Metabolic consequences of mitochondrial coenzyme A deficiency in patients with PANK2 mutations Mol. Genet. Metab. 105 2012 463 471
103. G. Zuliani, M.P. Donnorso, C. Bosi, A. Passaro, E. Dalla Nora, A. Zurlo, F. Bonetti, A.F. Mozzi, and C. Cortese Plasma 24S-hydroxycholesterol levels in elderly subjects with late onset Alzheimer's disease or vascular dementia: a case-control study BMC Neurol. 11 2011 121
104. L. Iuliano, R. Monticolo, G. Straface, I. Spoletini, W. Gianni, C. Caltagirone, P. Bossù, and G. Spalletta Vitamin E and enzymatic/oxidative stress-driven oxysterols in amnestic mild cognitive impairment subtypes and Alzheimer's disease J. Alzheimers Dis. 21 2010 1383 1392
105. D. Lütjohann, A. Papassotiropoulos, I. Björkhem, S. Locatelli, M. Bagli, R.D. Oehring, U. Schlegel, F. Jessen, M.L. Rao, K. von Bergmann, and R. Heun Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients J. Lipid Res. 41 2000 195 198
106. J.N. Noseworthy, C. Lucchinetti, M. Rodriguez, and B.G. Weinshenker Multiple sclerosis New Engl. J. Med. 343 2000 938 952
107. A. Cifelli, M. Arridge, P. Jezzard, M.M. Esiri, J. Palace, and P.M. Matthews Thalamic neurodegeneration in multiple sclerosis Ann. Neurol. 52 2002 650 653
108. V. Leoni, T. Masterman, P. Patel, S. Meaney, U. Diczfalusy, and I. Björkhem Side-chain oxidised oxysterols in cerebrospinal fluid and integrity of blood-brain barrier J. Lipid Res. 44 2003 793 799
109. V. Leoni, and C. Caccia Oxysterols as biomarkers in neurodegenerative diseases Chem. Phys. Lipids 164 2011 515 524
110. J. Zhang, and G. Hutton Role of magnetic resonance imaging and immunotherapy in treating multiple sclerosis Annu. Rev. Med. 56 2005 273 302
111. A.G. Kermode, P.S. Tofts, A.J. Thompson, D.G. MacManus, P. Rudge, B.E. Kendall, D.P. Kingsley, I.F. Moseley, E.P. du Boulay, and W.I. McDonald Heterogenity of blood-brain barrier changes in multiple sclerosis, an MRI study with gadolinium-DTPA enhancement Neurology 40 1990 229 235
112. J.H. van Waesberghe, M.A. van Walderveen, J.A. Castelijns, P. Scheltens, A. Lycklama, G.J. Nijeholt, C.H. Polman, and F. Barkhof Patterns of lesion development in multiple sclerosis, longitudinal observations with T1-weighted spin-echo and magnetization transfer MR Am. J. Neuroradiol. 19 1998 675 683
113. F. Bagnato, N. Jeffreis, N.D. Richert, R.D. Stone, J.M. Ohayon, H. McFarland, and J.A. Frank Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years Brain 126 2003 1782 1789
114. L. Truyen, J.H.T.M. van Waesberghe, M.A.A. van Walderveen, B.W. vanOosten, C.H. Polman, O.R. Hommes, H.J.A. Ader, and F. Barkhof Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis Neurology 47 1996 1469 1476
115. V. Leoni, T. Mastermann, F.S. Mousavi, B. Wretlind, L.O. Wahlund, U. Diczfalusy, J. Hillert, and I. Björkhem Diagnostic use of cerebral and extracerebral oxysterols Clin. Chem. Lab. Med. 42 2004 186 191
116. K. Blennow, M.J. de Leon, and H. Zetterberg Alzheimer disease Lancet 368 2006 387 403
117. E.R. Frears, D.J. Stephens, C.E. Walters, H. Davies, and B.M. Austen The role of cholesterol in the biosynthesis of beta-amyloid Neuroreport 10 1999 1699 1705
118. G. Di Paolo, and T.W. Kim Linking lipids to Alzheimer's disease: cholesterol and beyond Nat. Rev. Neurosci. 12 2011 284 296
119. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nat. Rev. Neurol. 6 2010 131 144
120. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, M.W. Weiner, R.C. Petersen, and J.Q. Trojanowski Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol. 9 2010 119 128
121. C.R. Jack Jr., V.J. Lowe, S.D. Weigand, H.J. Wiste, M.L. Senjem, D.S. Knopman, M.M. Shiung, J.L. Gunter, B.F. Boeve, B.J. Kemp, M. Weiner, R.C. Petersen, and Alzheimer's Disease Neuroimaging Initiative Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease, implications for sequence of pathological events in Alzheimer's disease Brain 132 2009 1355 1365
122. M. Kivipelto, and A. Solomon Cholesterol as a risk factor for Alzheimer's disease-epidemiological evidence Acta Neurol. Scand. Suppl. 185 2006 50 57
123. A.M. Saunders, W.J. Strittmatter, D. Schmechel, P.H. George-Hyslop, M.A. Pericak-Vance, S.H. Joo, B.L. Rosi, J.F. Gusella, D.R. Crapper-MacLachlan, and M.J. Alberts Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease Neurology 43 1993 1467 1472
124. S. Bodovitz, and W.L. Klein Cholesterol modulates á-secretase cleavage of amyloid precursor protein J. Biol. Chem. 271 1996 4436 4440
125. N.C. Fox, R.I. Scahill, W.R. Crum, and M.N. Rossor Correlation between rates of brain atrophy and cognitive decline in AD Neurology 52 1999 1687 1689
126. C.R. Jack Jr., R.C. Petersen, Y. Xu, P.C. O'Brien, G.E. Smith, R.J. Ivnik, E.G. Tangalos, and E. Kokmen Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease Neurology 51 1998 993 999
127. A. Besga, A. Cedazo-Minguez, I. Kåreholt, A. Solomon, I. Björkhem, B. Winblad, V. Leoni, B. Hooshmand, G. Spulber, A. Gonzalez-Pinto, M. Kivipelto, and L.O. Wahlund Differences in brain cholesterol metabolism and insulin in two subgroups of patients with different CSF biomarkers but similar white matter lesions suggest different pathogenic mechanisms Neurosci. Lett. 510 2012 121 126
128. H. Qureischie, R. Heun, D. Lütjohann, J. Popp, F. Jessen, C. Ledschbor-Frahnert, H. Thiele, W. Maier, F. Hentschel, P. Kelemen, and H. Kölsch CETP polymorphisms influence cholesterol metabolism but not Alzheimer's disease risk Brain Res. 1232 2008 1 6
129. C.E. Teunissen, D. Lütjohann, K. von Bergmann, F. Verhey, F. Vreeling, A. Wauters, E. Bosmans, H. Bosma, M.P. van Boxtel, M. Maes, J. Delanghe, H.J. Blom, M.M. Verbeek, P. Rieckmann, C. De Bruijn, H.W. Steinbusch, and J. de Vente Combination of serum markers related to several mechanisms in Alzheimer's disease Neurobiol. Aging 24 2003 893 902
130. P. Vemuri, H.J. Wiste, S.D. Weigand, L.M. Shaw, J.Q. Trojanowski, M.W. Weiner, D.S. Knopman, R.C. Petersen, C.R. Jack, and Alzheimer's Disease Neuroimaging Initiative MRI and CSF biomarkers in normal, MCI, and AD subjects, diagnostic discrimination and cognitive correlations Neurology 73 2009 287 293
131. J.L. Whitwell, S.A. Przybelski, S.D. Weigand, D.S. Knopman, B.F. Boeve, R.C. Petersen, and R.J. Clifford Jr. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease Brain 130 2007 1777 1786
132. T.M. Hughes, L.H. Kuller, O.L. Lopez, J.T. Becker, R.W. Evans, K. Sutton-Tyrrell, and C. Rosano Markers of cholesterol metabolism in the brain show stronger associations with cerebrovascular disease than Alzheimer's disease J. Alzheimers Dis. 30 2012 53 61
133. E.E. Smith, S. Egorova, D. Blacker, R.J. Killiany, A. Muzikansky, B.C. Dickerson, R.E. Tanzi, M.S. Albert, S.M. Greenberg, and C.R. Guttmann Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia Arch. Neurol. 65 2008 94 100
134. E.P. Helzner, J.A. Luchsinger, N. Scarmeas, S. Cosentino, A.M. Brickman, M.M. Glymour, and Y. Stern Contribution of vascular risk factors to the progression in Alzheimer disease Arch. Neurol. 66 2009 343 348
135. Z. Krištofiková, Z. Køíž, D. Rípová, and J. Koèa Interactions of amyloid â peptide 1-40 and cerebrosterol Neurochem. Res. 37 2012 604 613
136. R. Stewart, L.R. White, Q.L. Xue, and L.J. Launer Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study Arch. Neurol. 64 2007 103 107
137. M.M. Mielke, P.P. Zandi, M. Sjogren, D. Gustafson, S. Ostling, B. Steen, and I. Skoog High total cholesterol levels in late-life associated with a reduced risk of dementia Neurology 64 2005 1689 1695
138. A. Solomon, M. Kivipelto, B. Wolozin, J. Zhou, and R.A. Whitmer Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later Dement. Geriatr. Cogn. Disord. 28 2009 75 80
139. A. Solomon, I. Kåreholt, T. Ngandu, B. Winblad, A. Nissinen, J. Tuomilehto, H. Soininen, and M. Kivipelto Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study Neurology 68 2007 751 756
140. C.E. Teunissen, J. De Vente, K. von Bergmann, H. Bosma, M.P. van Boxtel, C. De Bruijn, J. Jolles, H.W. Steinbusch, and D. Lütjohann Serum cholesterol, precursors and metabolites and cognitive performance in an aging population Neurobiol. Aging 24 2003 147 155
141. T.N. van den Kommer, M.G. Dik, H.C. Comijs, D. Lütjohann, P. Lips, C. Jonker, and D.J. Deeg The role of extracerebral cholesterol homeostasis and ApoE e4 in cognitive Decline Neurobiol. Aging 33 2012 17 28
142. B.W. Schalk, M. Visser, D.J. Deeg, and L.M. Bouter Lower levels of serum albumin and total cholesterol and future decline in functional performance in older persons: the Longitudinal Aging Study Amsterdam Age Ageing 33 2004 266 272
143. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 6 1993 Mar 26 971 983
144. J.P. Vonsattel, R.H. Myers, T.J. Stevens, R.J. Ferrante, E.D. Bird, and E.P. Richardson Jr. Neuropathological classification of Huntington's disease J. Neuropathol. Exp. Neurol. 44 1985 559 577
145. E.H. Aylward Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease Brain Res. Bull. 72 2007 152 158
146. J.M. Gil, and A.C. Rego Mechanisms of neurodegeneration in Huntington's disease Eur. J. Neurosci. 27 2008 2803 2820
147. M. Valenza, and E. Cattaneo Emerging roles for cholesterol in Huntington's disease Trends Neurosci. 34 2011 474 486
148. M. Valenza, D. Rigamonti, D. Goffredo, C. Zuccato, S. Fenu, L. Jamot, A. Strand, A. Tarditi, B. Woodman, M. Racchi, C. Mariotti, S. Di Donato, A. Corsini, G. Bates, R. Pruss, J.M. Olson, S. Sipione, M. Tartari, and E. Cattaneo Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease J. Neurosci. 25 2005 9932 9939
149. M. Valenza, V. Leoni, A. Tarditi, C. Mariotti, I. Bjorkhem, S. Di Donato, and E. Cattaneo Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington's disease Neurobiol. Dis. 28 2007 133 142
150. M. Valenza, V. Leoni, J.M. Karasinska, L. Petricca, J. Fan, J. Carroll, M.A. Pouladi, E. Fossale, H.P. Nguyen, O. Riess, M. MacDonald, C. Wellington, S. DiDonato, M. Hayden, and E. Cattaneo Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes J. Neurosci. 30 2010 10844 10850
151. J.J. Ritch, A. Valencia, J. Alexander, E. Sapp, L. Gatune, G.R. Sangrey, S. Sinha, C.M. Scherber, S. Zeitlin, G. Sadri-Vakili, D. Irimia, M. Difiglia, and K.B. Kegel Multiple phenotypes in Huntington disease mouse neural stem cells Mol. Cell. Neurosci. 50 2012 70 81
152. E. Trushina, R.D. Singh, R.B. Dyer, S. Cao, V.H. Shah, R.G. Parton, R.E. Pagano, and C.T. McMurray Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo Hum. Mol. Genet. 15 2006 3578 3591
153. D. del Toro, X. Xifró, A. Pol, S. Humbert, F. Saudou, J.M. Canals, and J. Alberch Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington's disease J. Neurochem. 115 2010 153 167
154. J.Y. Li, M. Plomann, and P. Brundin Huntington's disease: a synaptopathy? Trends Mol. Med. 9 2003 414 420
155. M.S. Levine, C. Cepeda, M.A. Hickey, S.M. Fleming, and M.F. Chesselet Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect Trends Neurosci. 27 2004 691 697
156. J.G. Schulz, J. Bosel, M. Stoeckel, D. Megow, U. Dirnagl, and M. Endres HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis J. Neurochem. 89 2004 24 32
157. M. Futter, H. Schoenmakers, O. Sadiq, K. Chatterjee, and D.C. Rubinsztein Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors J. Med. Genet. 46 2009 438 446
158. R.H. Myers, J.P. Vonsattel, P.A. Paskevich, D.K. Kiely, T.J. Stevens, L.A. Cupples, E.P. Richardson Jr., and E.D. Bird Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus J. Neuropathol. Exp. Neurol. 50 1991 729 742
159. E. Gomez-Tortosa, M.E. MacDonald, J.C. Friend, S.A. Taylor, L.J. Weiler, L.A. Cupples, J. Srinidhi, J.F. Gusella, E.D. Bird, J.P. Vonsattel, and R.H. Myers Quantitative neuropathological changes in presymptomatic Huntington's disease Ann. Neurol. 49 2001 29 34
160. C. Fennema-Notestine, S.L. Archibald, M.W. Jacobson, J. Corey-Bloom, J.S. Paulsen, G.M. Peavy, A.C. Gamst, J.M. Hamilton, D.P. Salmon, and T.L. Jernigan In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease Neurology 63 2004 989 995
161. J.S. Paulsen, D.R. Langbehn, J.C. Stout, E. Aylward, C.A. Ross, M. Nance, M. Guttman, S. Johnson, M. MacDonald, L.J. Beglinger, K. Duff, E. Kayson, K. Biglan, I. Shoulson, D. Oakes, and M. Hayden Detection of Huntington's disease decades before diagnosis: the Predict-HD study J. Neurol. Neurosurg. Psychiatr. 79 2008 874 880
162. S.J. Tabrizi, D.R. Langbehn, B.R. Leavitt, R.A. Roos, A. Durr, D. Craufurd, C. Kennard, S.L. Hicks, N.C. Fox, R.I. Scahill, B. Borowsky, A.J. Tobin, H.D. Rosas, H. Johnson, R. Reilmann, B. Landwehrmeyer, and J.C. Stout TRACK-HD investigators, biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study, cross-sectional analysis of baseline data Lancet Neurol. 8 2009 791 801
163. P.C. Nopoulos, E.H. Aylward, C.A. Ross, J.A. Mills, D.R. Langbehn, H.J. Johnson, V.A. Magnotta, R.K. Pierson, L.J. Beglinger, M.A. Nance, R.A. Barker, and J.S. Paulsen Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment Brain 134 2011 137 142
164. H.D. Rosas, S.Y. Lee, A.C. Bender, A.K. Zaleta, M. Vangel, P. Yu, B. Fischl, V. Pappu, C. Onorato, J.H. Cha, D.H. Salat, and S.M. Hersch Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection" Neuroimage 49 2010 2995 3004
165. G. Bartzokis, P.H. Lu, T.A. Tishler, S.M. Fong, B. Oluwadara, J.P. Finn, D. Huang, Y. Bordelon, J. Mintz, and S. Perlman Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications Neurochem. Res. 32 2007 1655 1664
166. B.N. Finck, and D.P. Kelly PGC-1 coactivators: inducible regulators of energy metabolism in health and disease J. Clin. Invest. 116 2006 615 622
167. L. Cui, H. Jeong, F. Borovecki, C.N. Parkhurst, N. Tanese, and D. Krainc Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration Cell 127 2006 59 69
168. P. Weydt, V.V. Pineda, A.E. Torrence, R.T. Libby, T.F. Satterfield, E.R. Lazarowski, M.L. Gilbert, G.J. Morton, T.K. Bammler, A.D. Strand, L. Cui, R.P. Beyer, C.N. Easley, A.C. Smith, D. Krainc, S. Luquet, I.R. Sweet, M.W. Schwartz, and A.R. La Spada Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration Cell. Metab. 4 2006 349 362
169. R.K. Chaturvedi, P. Adhihetty, S. Shukla, T. Hennessy, N. Calingasan, L. Yang, A. Starkov, M. Kiaei, M. Cannella, J. Sassone, A. Ciammola, F. Squitieri, and M.F. Beal Impaired PGC-1alpha function in muscle in Huntington's disease Hum. Mol. Genet. 18 2009 3048 3065
170. R.K. Chaturvedi, N.Y. Calingasan, L. Yang, T. Hennessey, A. Johri, and M.F. Beal Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation Hum. Mol. Genet. 19 2010 3190 3205
171. S.J. McConoughey, M. Basso, Z.V. Niatsetskaya, S.F. Sleiman, N.A. Smirnova, B.C. Langley, L. Mahishi, A.J. Cooper, M.A. Antonyak, R.A. Cerione, B. Li, A. Starkov, R.K. Chaturvedi, M.F. Beal, G. Coppola, D.H. Geschwind, H. Ryu, L. Xia, S.E. Iismaa, J. Pallos, R. Pasternack, M. Hils, J. Fan, L.A. Raymond, J.L. Marsh, L.M. Thompson, and R.R. Ratan Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease EMBO Mol. Med. 2 2010 349 370
172. Z. Xiang, M. Valenza, L. Cui, V. Leoni, H.K. Jeong, E. Brilli, J. Zhang, Q. Peng, W. Duan, S.A. Reeves, E. Cattaneo, and D. Krainc Peroxisome- proliferator-activated receptor gamma coactivator 1 á contributes to dysmyelination in experimental models of Huntington's disease J. Neurosci. 31 2011 9544 9553
173. T. Lin, Z. Xiang, L. Cui, W. Stallcup, and S.A. Reeves New mouse oligodendrocyte precursor (mOP) cells for studies on oligodendrocyte maturation and function J. Neurosci. Methods 157 2006 187 194
174. T.C. Leone, J.J. Lehman, B.N. Finck, P.J. Schaeffer, A.R. Wende, S. Boudina, M. Courtois, D.F. Wozniak, N. Sambandam, C. Bernal-Mizrachi, Z. Chen, J.O. Holloszy, D.M. Medeiros, R.E. Schmidt, J.E. Saffitz, E.D. Abel, C.F. Semenkovich, and D.P. Kelly PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis PloS. Biol. 3 2005 e101
175. M. Markianos, M. Panas, N. Kalfakis, and D. Vassilopoulos Low plasma total cholesterol in patients with Huntington's disease and first-degree relatives Mol. Genet. Metab. 93 2008 341 346
176. L. Naia, M. João Ribeiro, and A.C. Rego Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q Rev. Neurosci. 2011 [Epub ahead of print]
177. R.C. Block, E.R. Dorsey, C.A. Beck, J.T. Brenna, and I. Shoulson Altered cholesterol and fatty acid metabolism in Huntington disease J. Clin. Lipidol. 4 2010 17 23
178. M.F. Weiner, G.L. Vega, R. Diaz-Arrastia, C. Moore, C. Madden, A. Hudak, and D. Lütjohann Plasma 24S-hydroxycholesterol and other oxysterols in acute closed head injury Brain Inj. 22 2008 611 615
179. S. Holdenrieder, D. Lütjohann, S. Geiger, K. von Bergmann, P. Stieber, and G.F. Hamann Does brain specific 24S-hydroxycholesterol in plasma indicate the disruption of blood-brain barrier in patients with ischemic stroke? Neurosci. Lett. 368 2004 201 204
180. G.B. Frisoni, N.C. Fox, C.R. Jack, P. Scheltenes, and P.M. Thomspon The clinical use of structural MRI in Alzheimer disease Nat. Rev. Neurol. 6 2010 67 77
181. M. Inglese, N. Oesingmann, P. Casaccia, and L. Fleysher Progressive multiple sclerosis and gray matter pathology: an MRI perspective Mt. Sinai J. Med. 78 2011 258 267
182. S.J. Tabrizi, R.I. Scahill, A. Durr, R.A. Roos, B.R. Leavitt, R. Jones, G.B. Landwehrmeyer, N.C. Fox, H. Johnson, S.L. Hicks, C. Kennard, D. Craufurd, C. Frost, D.R. Langbehn, R. Reilmann, J.C. Stout TRACK-HD Investigators Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis Lancet Neurol. 10 2011 31 42
183. M. Shafaati, A. Solomon, M. Kivipelto, I. Björkhem, and V. Leoni Levels of ApoE in cerebrospinal fluid are correlated with Tau and 24S-hydroxycholesterol in patients with cognitive disorders Neurosci. Lett. 425 2007 78 82